Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

BPC-157 Not Working Reasons Fix: Comparison

Reconstitution shear damage Injecting water directly onto powder, shaking vial after mixing None. Solution looks clear 40–60% loss within 24 hours Inject down vial wall at 45° angle, let dissolve passively for 10 min, never shake Temperature excursion (shippin

This comparison does not assign a generated winner or score.

  • Reconstitution shear damage
  • Injecting water directly onto powder, shaking vial after mixing
  • None. Solution looks clear
  • 40–60% loss within 24 hours
  • Inject down vial wall at 45° angle, let dissolve passively for 10 min, never shake
  • Temperature excursion (shipping)
  • Ice packs melt during transit, vial spends 6+ hours at 20–30°C
  • None. Peptide degradation is invisible
  • 15–30% loss per excursion event
  • Request signature-required delivery, refrigerate immediately upon arrival, discard if package feels warm
  • Oxidative degradation (vial reuse)
  • Repeated needle punctures introduce oxygen into headspace
  • Slight cloudiness after 3–4 weeks (late stage only)
  • 5–10% loss per week after day 21
  • Use vial within 28 days of reconstitution, store with minimal air headspace, use bacteriostatic water only
  • Underdosing relative to half-life
  • Injecting once daily when half-life is 4–6 hours
  • None. Dosing schedule issue, not peptide issue
  • Effective plasma levels drop 50% between doses
  • Switch to twice-daily dosing (morning + evening) to maintain therapeutic levels
  • Injection site poor absorption
  • Injecting into scar tissue or areas with low vascularity
  • None. Absorption variability issue
  • Variable. Can be 30–50% reduced uptake
  • Rotate injection sites, target areas with good subcutaneous blood flow (abdomen, outer thigh)
  • Professional Assessment
  • Most BPC-157 failures trace to preparation errors, not compound inefficacy. Fixing the root cause (reconstitution technique, storage discipline) restores expected results in 70–80% of cases
  • None initially. Degradation is cumulative and invisible until potency drops below therapeutic threshold
  • Combination failures (reconstitution + storage + dosing) can reduce effective potency by 60–80%
  • Audit entire process from shipping to injection. Most users find 2–3 fixable errors when they review step-by-step
More references

Related material